Argent Trust Co Buys 208 Shares of Humana Inc (NYSE:HUM)

Argent Trust Co increased its stake in Humana Inc (NYSE:HUM) by 4.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,924 shares of the insurance provider’s stock after purchasing an additional 208 shares during the period. Argent Trust Co’s holdings in Humana were worth $1,546,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Bartlett & Co. LLC bought a new position in Humana in the 1st quarter worth approximately $30,000. Lighthouse Financial Advisors Inc. bought a new stake in shares of Humana during the 4th quarter valued at $31,000. Valeo Financial Advisors LLC raised its position in shares of Humana by 66.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 93 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 37 shares during the last quarter. Sandy Spring Bank bought a new stake in shares of Humana during the 1st quarter valued at $32,000. Finally, 1776 Wealth LLC raised its position in shares of Humana by 307.7% during the 1st quarter. 1776 Wealth LLC now owns 106 shares of the insurance provider’s stock valued at $33,000 after acquiring an additional 80 shares during the last quarter. Hedge funds and other institutional investors own 93.22% of the company’s stock.

In other news, Director David A. Jr/Ky Jones sold 5,800 shares of the stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $256.19, for a total transaction of $1,485,902.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.42% of the company’s stock.

NYSE HUM traded down $0.84 on Friday, reaching $394.43. The company had a trading volume of 415,854 shares, compared to its average volume of 962,079. The firm has a market capitalization of $52.26 billion, a price-to-earnings ratio of 20.25, a price-to-earnings-growth ratio of 1.73 and a beta of 0.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.66 and a current ratio of 1.66. Humana Inc has a 1-year low of $208.25 and a 1-year high of $412.70. The company’s fifty day moving average is $361.93 and its 200-day moving average is $345.82.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.84 by $0.56. Humana had a net margin of 3.86% and a return on equity of 21.02%. The firm had revenue of $18.94 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same period in the prior year, the business earned $4.48 EPS. The company’s revenue for the quarter was up 17.6% compared to the same quarter last year. On average, research analysts forecast that Humana Inc will post 18.55 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.625 per share. The ex-dividend date of this dividend is Monday, June 29th. This represents a $2.50 dividend on an annualized basis and a dividend yield of 0.63%. Humana’s dividend payout ratio is 13.99%.

Several brokerages have commented on HUM. Mizuho upped their target price on shares of Humana from $405.00 to $420.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Morgan Stanley upped their target price on shares of Humana from $375.00 to $500.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating and set a $396.00 target price for the company. in a research report on Friday, April 17th. Barclays reiterated a “buy” rating on shares of Humana in a research report on Sunday, March 29th. Finally, Deutsche Bank upped their target price on shares of Humana from $363.00 to $433.00 and gave the company a “hold” rating in a research report on Tuesday, February 18th. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $405.42.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Do equity income investments outperform growth and income investments?

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.